Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

NEXT STORY
Clinical Trial Begins to Evaluate Physiological Effects of a Saturated Fat Found in Milk
PREV STORY
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting

Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patientsTranslational studies suggest ...

author_avatar
NASDAQ Market News

Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061

Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg ...

author_avatar
NASDAQ Market News

Tempus Announces Latest Immunotherapy Project

CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping ...

author_avatar
NASDAQ Market News